- cafead Jan 05, 2023 at 10:12: AM
via Horizon Therapeutics has announced the enrolment of the first patient in a Phase II clinical trial of its antibody daxdilimab for treating discoid lupus erythematosus (DLE).
The placebo-controlled, randomised trial has been designed to assess the company’s development-stage medicine daxdilimab for individuals with moderate-to-severe primary DLE, a rare, chronic, inflammatory skin condition.
article source
The placebo-controlled, randomised trial has been designed to assess the company’s development-stage medicine daxdilimab for individuals with moderate-to-severe primary DLE, a rare, chronic, inflammatory skin condition.
article source